Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
|
what is the primary risk factor of lung cancer
|
Smoking
-cessation leads to gradual decrease in risks but takes 5 years to see results |
|
|
what are the screening methods of lung cancer
|
no standard of care for screening of lung cancer
|
|
|
what can be done to prevent lung cancer
|
smoke cessation
beta-carotene has been shown to increase risk of lung cancer |
|
|
what type of lung cancer primarily metastasizes to the brain
|
small cell lung cancer
|
|
|
what are the types of Non Small Cell Lung Cancer
|
adenocarcinoma (peripheral)
squamous cell (central) large cell (peripheral) |
|
|
what are the treatment modalities of Non Small Cell Lung cancer
|
chemotherapy
targeted therapy surgery radiation |
|
|
what type of surgery can be done in NSCLC
|
lobectomy - remove entire lob
pneumonectomy - remove entire lung wedge resection/segmentectomy - remove slice of lobe |
|
|
what are the active agents used in chemotherapy for treatment of NSCLC
|
docetaxil
irinotecan pemetrexid carboplatin cisplatin paclitaxel vinorelbine gemcitabine etoposide topotecan |
|
|
in stage 1 disease of NSCLC what is the treatment
|
surgery
|
|
|
what kind of chemotherapy do NSCLC patients get
|
adjuvant
neoadjuvant (stage 3A) |
|
|
how do you treat NSCLC patients with Stage 4 disease
|
goal is palliation
surgery not done chemotherapy is standard of care radiation done for palliation only |
|
|
what is the frontline chemotherapy regimens for NSCLC
|
platin (cisplatin or carboplatin) + something else
platin based doublet |
|
|
what is the best tolerated platin based doublet
|
carboplatin + paclitaxel
|
|
|
out of cisplatin + pemetrexed vs cisplatin + gemcitabine what subset of NSCLC does one treat better than the other
|
cisplatin + pemetrexed better at treating non squamous NSCLC
cisplatin + gemcitabine better at treating squamous NSCLC |
|
|
what agents are used for targeted therapy in treating NSCLC patients
|
Bevacizumab
Cetuximab Crizotinib Erlotinib |
|
|
what patient population can receive Bevacizumab and how is it given
|
non squamous patients only
Bevacizumab is given in combination with carboplatin and paclitaxel |
|
|
what combination is Cetuximab given in
|
with cisplatin and vinorelbine
|
|
|
what patient population is Crizotinib given in
|
ALK+ PATIENTS ONLY
|
|
|
what patient population is Erlotinib given in
|
EGFR+ NSCLC
|
|
|
what drugs are used in maintenence therapy - continuation
|
bevacizumab - after cycles with platinum doublet (carboplatin + paclitaxel)
cetuximab - after cycles with cisplatin and vinorelbine pemetrexed - after cycles of cisplatin and pemetrexed for non squamous histology |
|
|
what drugs are used in maintanence therapy - switch
|
pemetrexed - non squamous
docetaxel - squamous erlotinib |
|
|
what are the stages of SCLC
|
limited
extensive |
|
|
what stage of SCLC is this:
can be safely encompassed within a single radiation port |
limited stage
if outside port then extensive stage |
|
|
what stage of Small cell lung cancer involves curative treatment
|
limited stage only
|
|
|
what are the treatment modalities for small cell lung cancer
|
chemotherapy
radiation -chest (palliative) -brain (palliative): PCI |
|
|
what is the drug regimen to treat limited stage SCLC
|
cisplatin + etoposide
chemotherapy given concurrently with radiation consider prophylactic cranial irradiation if complete response to initial therapy |
|
|
what is the drug regimen to treat extensive stage SCLC
|
carboplatin + etoposide
cisplatin + etoposide cisplatin + irinotecan radiation for palliative treatment of chest |
|
|
read up on recurrence/relapse treatment
|
read up on recurrence/relapse treatment
|
